TTKHLTCARE

TTK Healthcare Share Price

 

 

Invest in TTK Healthcare with 1X leverage

Invest with MTF

Performance

  • Low
  • ₹1,002
  • High
  • ₹1,019
  • 52 Week Low
  • ₹994
  • 52 Week High
  • ₹1,399
  • Open Price₹1,019
  • Previous Close₹1,011
  • Volume2,116
  • 50 DMA₹1,076.37
  • 100 DMA₹1,119.52
  • 200 DMA₹1,181.90

Investment Returns

  • Over 1 Month -7.52%
  • Over 3 Month -14.36%
  • Over 6 Month -24.45%
  • Over 1 Year -26.5%

Smart Investing Starts Here Start SIP with TTK Healthcare for Steady Growth!

Invest Now

TTK Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.4
  • PEG Ratio
  • -1.3
  • Market Cap Cr
  • 1,420
  • P/B Ratio
  • 1.3
  • Average True Range
  • 25.87
  • EPS
  • 49.98
  • Dividend Yield
  • 1
  • MACD Signal
  • -20.99
  • RSI
  • 26.37
  • MFI
  • 16.07

TTK Healthcare Financials

TTK Healthcare Technicals

EMA & SMA

Current Price
₹1,004.90
-5.7 (-0.56%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,037.53
  • 50 Day
  • ₹1,076.37
  • 100 Day
  • ₹1,119.52
  • 200 Day
  • ₹1,181.90

Resistance and Support

1008.57 Pivot Speed
  • R3 1,031.93
  • R2 1,025.37
  • R1 1,015.13
  • S1 998.33
  • S2 991.77
  • S3 981.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

TTK Healthcare Ltd. operates across diverse sectors, offering pharmaceuticals, medical devices, consumer products, and animal care solutions. With a strong presence in India, it provides trusted healthcare and wellness products that cater to both domestic and global markets.

T T K Healthcare (Nse) has an operating revenue of Rs. 825.10 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 14% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 27 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 71 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

TTK Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-22 Quarterly Results
2025-10-17 Quarterly Results
2025-08-04 Quarterly Results
2025-05-23 Audited Results & Final Dividend
2025-01-24 Quarterly Results & Others To consider other business matters. per share(60%)Final Dividend
Date Purpose Remarks
2025-07-18 FINAL Rs.10.00 per share(100%)Final Dividend
View TTK Healthcare Dividend History Arrow

TTK Healthcare F&O

TTK Healthcare Shareholding Pattern

74.56%
0%
1.9%
0.01%
15.89%
7.64%

About TTK Healthcare

  • NSE Symbol
  • TTKHLTCARE
  • BSE Symbol
  • 507747
  • Managing Director & CEO
  • Mr. S Kalyanaraman
  • ISIN
  • INE910C01018

Similar Stocks to TTK Healthcare

TTK Healthcare FAQs

TTK Healthcare share price is ₹1,004 As on 09 January, 2026 | 04:45

The Market Cap of TTK Healthcare is ₹1420 Cr As on 09 January, 2026 | 04:45

The P/E ratio of TTK Healthcare is 21.4 As on 09 January, 2026 | 04:45

The PB ratio of TTK Healthcare is 1.3 As on 09 January, 2026 | 04:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23